# Annex: Questionnaire for private sector stakeholders, specific to the ABS of the Nagoya Protocol

Background:

The Nagoya Protocol on Access to Genetic Resources and Benefit-sharing, a complementary agreement to the Convention on Biological Diversity, adds new requirements for compliance with national laws and conditions of providers of genetic resources, including the monitoring their use. In Morocco, the Nagoya Protocol is currently being implemented and a national ABS legislation is being developed.

As part of a doctoral thesis research and in coordination with the government's national focal point on ABS, this survey aims to measure the level of integration that private entities operating in key sectors such as biotechnology, pharmacy and cosmetics aim to have with regard to the alignment with the Nagoya Protocol and its implementation in Morocco. The results of this survey will identify the expectations of the private sector and take into account its concerns for access and use of genetic resources in Morocco, and produce recommendations for the government, which can adapt its future ABS legislation to the applied use of genetic resources in these key sectors.

We would like to thank in advance everyone who devoted their time to completing this questionnaire and is thus contributing to the completion of this work.

The information from this questionnaire will only be used for the purposes of comparative data analysis and the identities of the contributors will not be published on an individual basis.

General Questions:

1. Does your company support operating in compliance with the Nagoya Protocol and international regulations on access and benefit sharing (ABS) arising from the use of genetic resources (*only one answer possible*)?
   * Yes
   * No
2. In your opinion, monetary benefits should be shared primarily with (*multiple responses possible*):
   * The local population living/dependent on the ecosystem where the genetic resource is located?
   * The main actors in the value chain of the genetic resource?
   * Government or competent authorities that are sovereign of the genetic resource?
3. In your opinion, non-monetary benefits should be shared primarily with (*multiple responses possible*):
   * The local population living/dependent on the ecosystem where the genetic resource is located?
   * The main actors in the value chain of the genetic resource?
   * Government or competent authorities that are sovereign of the genetic resource?
4. In the absence of specific ABS legislation in a country providing genetic resources, does your company practice sustainable sourcing of these resources, governed by other sectoral, national or international ABS or BioTrade regulations (*only one answer possible*)?
   * Yes
   * No
5. In your opinion, the difficulties encountered in accessing a country's genetic resources and entering into an ABS contract with mutually agreed terms (MAT) are mainly due to (*multiple responses possible*):
   * Scarcity and/or lack of information on the genetic resource concerned
   * Lack of clarity and transparency regarding ABS requirements in the country providing the genetic resource
   * ABS requirements that are inadequate and not adapted to the realities of the sector in which you operate, in the country providing the genetic resource
   * The time required for the competent authorities in the country providing the genetic resource to respond and/or process access requests

Questions specific to Morocco:

1. Has your company ever used genetic resources from Morocco or is it interested in using genetic resources from Morocco in the future (*only one answer possible*)?
   * Yes
   * No
2. Has your company ever attempted to access genetic resources from Morocco under the terms of ABS as established by the Nagoya Protocol (by contacting the Moroccan National ABS Focal Point or the National Competent Authority) (*only one answer possible*)?
   * Yes
   * No
3. In order to access genetic resources from Morocco, would you consider cooperating with local companies/institutions/research institutions in Morocco (*only one answer possible*)?
   * Yes
   * No
4. Do you plan to use traditional knowledge held by local populations in Morocco in addition to the use of a genetic resource in your R&D activities (*only one answer possible)?* 
   * Yes, systematically
   * No, only the material genetic resource is considered
   * This depends on national regulations and the availability of information on traditional knowledge related to the genetic resource
5. In your opinion, after developing and signing an ABS contract with a genetic resource provider in Morocco, monitoring and control measures for the resource would be (*multiple responses possible*):
   * Complex and time-consuming, creating a barrier to R&D activities
   * Unnecessary as already covered by the Nagoya Protocol's monitoring and compliance measures (International Certificate of Compliance and reporting of checkpoints in the CBD Secretariat's ABS Clearing House)
   * Unnecessary as already covered by the control and compliance measures of the country of the user of the genetic resource
   * Necessary and requiring a detailed procedure in the national ABS legislation with which the user of the genetic resource must comply
6. What improvements do you think should be made for a better implementation of ABS in Morocco, in order to access Morocco's genetic resources within the standards of the Nagoya Protocol (*several answers possible*)?
   * An ABS legal framework that is better adapted to and more in tune with the realities of the sectors using genetic resources
   * Simplified/more efficient administrative procedures and improved governance over genetic resources
   * More availability of information on biological/genetic resources, existing ABS standards and points of contact to engage
   * No improvement is necessary
7. Open-ended question: What would be your expectations of providers of genetic resources, as well as of the competent authorities regarding ABS in Morocco? Please fill in the box below with recommendations or comments (e.g., changes to regulations, response times for access requests, provision of information on ABS procedures, etc.)

*Write your answer here*